筋骨格障害治療薬の世界市場:リウマチ性関節炎、骨関節炎、骨粗鬆症、乾癬性関節炎、強直性脊椎炎、線維筋痛症...市場調査レポートについてご紹介

【英文タイトル】Global Musculoskeletal Disorders Therapeutics Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Pipeline portfolio

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by disease type
• Rheumatoid arthritis
• Osteoarthritis
• Osteoporosis
• Psoriatic arthritis
• Ankylosing spondylitis
• Fibromyalgia

PART 08: Global rheumatoid arthritis drugs market
• Market overview

PART 09: Global osteoarthritis drugs market
• Market overview

PART 10: Global osteoporosis drugs market
• Market overview

PART 11: Global ankylosing spondylitis drugs market
• Market overview

PART 12: Global psoriatic arthritis drugs market
• Market overview

PART 13: Global fibromyalgia drugs market
• Market overview

PART 14: Market segmentation by type of molecule
• Biologics
• Small molecules

PART 15: Market segmentation by route of administration
• Parenteral
• Topical
• Oral

PART 16: Geographical segmentation
• Global musculoskeletal disorder therapeutics market by geography 2015-2020
• Musculoskeletal disorders therapeutics market in Americas
• Musculoskeletal disorders therapeutics market in EMEA
• Musculoskeletal disorders therapeutics market in APAC

PART 17: Market drivers
• High growth potential of mAbs
• Unmet needs of therapeutics
• Tentative approval of advanced drugs
• Technological advancements in medical imaging
• Combination therapies

PART 18: Impact of drivers

PART 19: Market challenges
• Non-adherence to treatment regimen
• Growing preference toward surgeries
• Multiple patent expiries

PART 20: Impact of drivers and challenges

PART 21: Market trends
• Focus on regenerative medicines
• Ongoing active clinical trials for biosimilars
• Growing focus toward abuse-resistant novel drugs

PART 22: Vendor landscape
• Competitive scenario

PART 23: Key vendor analysis
• AbbVie
• Johnson & Johnson
• Amgen
• Pfizer
• F. Hoffmann-La Roche
• Eli Lilly
• Other prominent vendors

PART 24: Appendix
• List of abbreviations

PART 25: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments for musculoskeletal disorder therapeutics
Exhibit 03: Impact of biologics on various sectors
Exhibit 04: Pipeline portfolio: Global rheumatoid arthritis drugs market
Exhibit 05: Pipeline portfolio: Global osteoarthritis drugs market
Exhibit 06: Pipeline portfolio: Global osteoporosis drugs market
Exhibit 07: Pipeline portfolio: Global psoriatic arthritis drugs market
Exhibit 08: Pipeline portfolio: Global fibromyalgia drugs market
Exhibit 09: Pipeline portfolio: Global ankylosing spondylitis drugs market
Exhibit 10: Global musculoskeletal disorder therapeutics market 2015-2020 ($ billions)
Exhibit 11: Patient assistance programs offered by companies
Exhibit 12: CAM therapies for rheumatoid arthritis
Exhibit 13: Five forces analysis
Exhibit 14: Segmentation of global musculoskeletal disorder therapeutics market
Exhibit 15: Segmentation of global musculoskeletal disorder therapeutics market by revenue 2015
Exhibit 16: Opportunities in rheumatoid arthritis drugs industry
Exhibit 17: Global rheumatoid arthritis drugs market 2015-2020 ($ billions)
Exhibit 18: Unmet medical needs with current osteoarthritis treatments
Exhibit 19: Global osteoarthritis drugs market 2015-2020 ($ billions)
Exhibit 20: Global osteoporosis drugs market 2015-2020 ($ billions)
Exhibit 21: Global ankylosing spondylitis drugs market 2015-2020 ($ billions)
Exhibit 22: Global psoriatic arthritis drugs market 2015-2020 ($ billions)
Exhibit 23: Global fibromyalgia drugs market 2015-2020 ($ billions)
Exhibit 24: Segmentation of global musculoskeletal disorder therapeutics market by type of molecules 2015
Exhibit 25: Segmentation of global musculoskeletal disorder therapeutics market by ROA 2015
Exhibit 26: Global musculoskeletal disorder therapeutics market by geography 2015-2020
Exhibit 27: Global musculoskeletal disorder therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 28: Global share of musculoskeletal disorders therapeutics market by geography 2015
Exhibit 29: Global musculoskeletal disorder therapeutics market: Country analysis based on revenue and growth rate
Exhibit 30: Musculoskeletal disorders therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 31: Musculoskeletal disorders therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 32: Musculoskeletal disorders therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 33: Few of the late-stage mAbs under development for various musculoskeletal disorders
Exhibit 34: Impact of drivers
Exhibit 35: Approval and patent expiries of top selling biologics
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Key vendors ranking 2015
Exhibit 38: Geographical presence of key vendors
Exhibit 39: Competitive scenario of global musculoskeletal disorder therapeutics market vendors 2015-2020
Exhibit 40: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 41: AbbVie: Geographical segmentation of Humira 2015
Exhibit 42: AbbVie: Metrics analysis
Exhibit 43: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 44: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 45: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions)
Exhibit 46: Johnson & Johnson: YoY revenue and growth rate of Stelara 2013-2015 ($ billions)
Exhibit 47: Johnson & Johnson: Metrics analysis
Exhibit 48: Amgen: YoY revenue and growth rate of Enbrel (US and Canada) 2013-2015 ($ billions)
Exhibit 49: Amgen: YoY revenue and growth rate of Prolia 2013-2015 ($ billions)
Exhibit 50: Amgen: Geographical segmentation of Prolia 2015
Exhibit 51: Amgen: Metrics analysis
Exhibit 52: Key products in musculoskeletal disorders market with 2015 revenues
Exhibit 53: Pfizer: YoY revenue and growth rate of Lyrica 2013-2015 ($ billions)
Exhibit 54: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 55: Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ billions)
Exhibit 56: Pfizer: YoY revenue and growth rate of Xeljanz 2013-2015 ($ millions)
Exhibit 57: Pfizer: Metrics analysis
Exhibit 58: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan 2013-2015 ($ billions)
Exhibit 59: F. Hoffmann-La Roche: Geographical segmentation of MabThera/Rituxan by revenue 2015
Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)
Exhibit 61: F. Hoffmann-La Roche: Geographical segmentation of Actemra/RoActemra by revenue 2015
Exhibit 62: F. Hoffmann-La Roche: Metrics analysis
Exhibit 63: Eli Lilly: YoY revenue and growth rate of Cymbalta 2013-2015 ($ billions)
Exhibit 64: Eli Lilly: YoY revenue and growth rate of Evista 2013-2015 ($ billions)
Exhibit 65: Eli Lilly: Geographical segmentation of Evista 2015
Exhibit 66: Eli Lilly: YoY revenue and growth rate of Forteo 2013-2015 ($ billions)
Exhibit 67: Eli Lilly: Geographical segmentation of Forteo 2015
Exhibit 68: Eli Lilly: Metrics analysis


【レポート販売概要】

■ タイトル:筋骨格障害治療薬の世界市場:リウマチ性関節炎、骨関節炎、骨粗鬆症、乾癬性関節炎、強直性脊椎炎、線維筋痛症
■ 英文:Global Musculoskeletal Disorders Therapeutics Market 2016-2020
■ 発行日:2016年8月31日
■ 調査会社:Technavio
■ 商品コード:IRTNTR10170
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。